DURHAM, N.C., March 28, 2011 /PRNewswire/ — Chimerix,
Inc., a pharmaceutical company developing orally-available
antiviral therapeutics, announced today that Timothy W. Trost has
joined the company as Senior Vice President, Chief Financial
Officer.
Mr. Trost brings to Chimerix more than 30 years of experience
working in the financial field, combining strong executive
management skills with an extensive financial background. In
this newly-created position, Mr. Trost will be responsible for
overseeing the company’s financial operations, reporting to Kenneth
I. Moch, Chimerix’s President and Chief Executive Officer.
“Tim is a seasoned industry executive whose depth and breadth of
leadership experience significantly strengthen the Chimerix
management team,” said Mr. Moch. “Tim has been consulting for
Chimerix since last fall and has been an important part of the team
in securing both the recently announced Series F financing as well
as the BARDA contract.”
Prior to joining Chimerix, Mr. Trost was Vice President and CFO
at Argos Therapeutics, Inc., a venture-backed immunotherapy company
located in Research Triangle Park. Previously, he was Senior
Vice President and CFO at InteCardia, Inc., a venture-backed
cardiac imaging company. While at InteCardia, Mr. Trost
played a key role in negotiating and executing the sale of the
company to Syncor International Corporation. Prior to InteCardia,
Mr. Trost served as Executive Vice President and CFO of Coastal
Physician Group, Inc., a contract provider of emergency room
physicians, having joined the company as Vice President of
Corporate Development. He also held the positions of Vice
President of Finance at Morganite North America, Inc., and Senior
Manager at Price Waterhouse. Mr. Trost holds a B.S. in
Accounting from the University of Illinois at Urbana-Champaign and
is a Certified Public Accountant.
About Chimerix
Chimerix is developing novel ant
‘/>”/>